FOI Request 808

Numbers of patients treated with the new oral anti-coagulation treatments:
The Trust does not initiate these treatments: any usage would be as a result of
continuing supply when a patient has become an inpatient. As such we have not
treated patients with these drugs.
Drug
Number patients treated in the last 3
months
Rivaroxaban (Xarelto)
Dabigatran (Pradaxa)
Apixaban (Eliquis)

If possible, please split the patients by the following diagnosis;
The Trust does not initiate these treatments: any usage would be as a result of
continuing supply when a patient has become an inpatient. As such we have not
treated patients with these drugs.
Drug
Rivaroxaban
(Xarelto)
Dabigatran
(Pradaxa)
Apixaban (Eliquis)
Acute
cardiac Venous Thrombo- Prophylaxis of VTE
syndrome (ACS)
embolism (VTE)

What is the usual dose/strength for the following treatments, for each of the
indications listed:
The Trust does not initiate these treatments: any usage would be as a result of
continuing supply when a patient has become an inpatient. As such we have not
treated patients with these drugs.
Drug
Typical does for VTE Typical dose for Typical dose for
prophylaxis
ACS
AF
Rivaroxaban
(Xarelto)
Dabigatran
(Pradaxa)
Apixaban (Eliquis)

Please fill in the following table relating to dispensed items in the last 3 months:
Drug & strength
Number
of
dispensed
pharmacy
(Xarelto) 3
Rivaroxaban
20mg
Rivaroxaban (Xarelto)
10mg
Rivaroxaban (Xarelto)
15mg
Dabigatran
(Pradaxa)
110mg
Dabigatran
(Pradaxa)
75mg
Dabigatran
(Pradaxa)
150mg
Apixaban
(Eliquis)
2.5mg
Apixaban (Eliquis) 5mg
1
0
0
0
0
9
6
items
from